Fig. 2: The presence of anti-thyroid antibodies at baseline was associated with the development of destructive thyroiditis and/or hypothyroidism in patients treated with anti-PD-1 antibodies. | British Journal of Cancer

Fig. 2: The presence of anti-thyroid antibodies at baseline was associated with the development of destructive thyroiditis and/or hypothyroidism in patients treated with anti-PD-1 antibodies.

From: Anti-thyroid antibodies and thyroid echo pattern at baseline as risk factors for thyroid dysfunction induced by anti-programmed cell death-1 antibodies: a prospective study

Fig. 2

The cumulative incidence of destructive thyroiditis and/or hypothyroidism was significantly higher in the Abs-positive than Abs-negative group among patients treated with pembrolizumab (a), nivolumab (b) and pembrolizumab or nivolumab (c), respectively. Abs antibodies.

Back to article page